-
Product Insights
Streptococcal Pneumonia - Drugs In Development, 2024
Empower your strategies with our Streptococcal Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate...
-
Product Insights
Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2024
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions. Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia (HAP) drugs in development market research report...
-
Product Insights
Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
Community Acquired Pneumonia - Drugs In Development, 2024
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community Acquired Pneumonia drugs in development market research...
-
Product Insights
Community-Acquired Bacterial Pneumonia - Drugs In Development, 2024
Empower your strategies with our Community-Acquired Bacterial Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia is defined as pneumonia that is acquired outside the hospital. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, atypical bacteria (ie, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella species), and viruses. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia The Community-Acquired Bacterial Pneumonia drugs in development market research report provide comprehensive information...
-
Product Insights
Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hospital Acquired Pneumonia (HAP) Clinical Trial Report Overview A total of 581 HAP clinical trials were conducted as of April 2024. The HAP clinical trial report provides a comprehensive understanding of the HAP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe...
-
Product Insights
Ventilator Associated Pneumonia (VAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ventilator Associated Pneumonia (VAP) Clinical Trials Market Report Overview The Ventilator Associated Pneumonia (VAP) clinical trial market research report provides an overview of Ventilator Associated Pneumonia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Ventilator Associated Pneumonia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.